A daganatok immunterápiájának prediktív markerei, a PD-L1-meghatározás gyakorlati kérdései

Translated title of the contribution: Predictive markers of immunotherapy of cancer, practical issues of PD-L1 testing

Research output: Contribution to journalArticle

Abstract

Pathologists have detected signs of antitumor immune reactions for a long time but only in case of a few cancer types became this part of the report. The advent of immunotherapy of cancers, however, radically alters this routine and promotes the development of clinically valid prognostic and predictive immunological makers. The most advanced immunological markers are the Immunoscore (density of T-cell subpopulations), and PD-L1 protein expression on tumor or immune cells. PD-L1 testing of cancers raises new issues since almost all novel therapies developed its own in vitro diagnostics. Due to the incompatibility of these assays it is suggested to use the companion diagnostic of the given immunotherapeutic drug defined in its label.

Original languageHungarian
Pages (from-to)158-166
Number of pages9
JournalMagyar onkologia
Volume61
Issue number2
Publication statusPublished - Jun 6 2017

Fingerprint

Immunotherapy
Neoplasms
T-Lymphocytes
Pharmaceutical Preparations
Proteins
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A daganatok immunterápiájának prediktív markerei, a PD-L1-meghatározás gyakorlati kérdései. / Tímár, J.; Ladányi, A.

In: Magyar onkologia, Vol. 61, No. 2, 06.06.2017, p. 158-166.

Research output: Contribution to journalArticle

@article{49af81c5380642a085eb4afcadb75261,
title = "A daganatok immunter{\'a}pi{\'a}j{\'a}nak predikt{\'i}v markerei, a PD-L1-meghat{\'a}roz{\'a}s gyakorlati k{\'e}rd{\'e}sei",
abstract = "Pathologists have detected signs of antitumor immune reactions for a long time but only in case of a few cancer types became this part of the report. The advent of immunotherapy of cancers, however, radically alters this routine and promotes the development of clinically valid prognostic and predictive immunological makers. The most advanced immunological markers are the Immunoscore (density of T-cell subpopulations), and PD-L1 protein expression on tumor or immune cells. PD-L1 testing of cancers raises new issues since almost all novel therapies developed its own in vitro diagnostics. Due to the incompatibility of these assays it is suggested to use the companion diagnostic of the given immunotherapeutic drug defined in its label.",
author = "J. T{\'i}m{\'a}r and A. Lad{\'a}nyi",
year = "2017",
month = "6",
day = "6",
language = "Hungarian",
volume = "61",
pages = "158--166",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - A daganatok immunterápiájának prediktív markerei, a PD-L1-meghatározás gyakorlati kérdései

AU - Tímár, J.

AU - Ladányi, A.

PY - 2017/6/6

Y1 - 2017/6/6

N2 - Pathologists have detected signs of antitumor immune reactions for a long time but only in case of a few cancer types became this part of the report. The advent of immunotherapy of cancers, however, radically alters this routine and promotes the development of clinically valid prognostic and predictive immunological makers. The most advanced immunological markers are the Immunoscore (density of T-cell subpopulations), and PD-L1 protein expression on tumor or immune cells. PD-L1 testing of cancers raises new issues since almost all novel therapies developed its own in vitro diagnostics. Due to the incompatibility of these assays it is suggested to use the companion diagnostic of the given immunotherapeutic drug defined in its label.

AB - Pathologists have detected signs of antitumor immune reactions for a long time but only in case of a few cancer types became this part of the report. The advent of immunotherapy of cancers, however, radically alters this routine and promotes the development of clinically valid prognostic and predictive immunological makers. The most advanced immunological markers are the Immunoscore (density of T-cell subpopulations), and PD-L1 protein expression on tumor or immune cells. PD-L1 testing of cancers raises new issues since almost all novel therapies developed its own in vitro diagnostics. Due to the incompatibility of these assays it is suggested to use the companion diagnostic of the given immunotherapeutic drug defined in its label.

UR - http://www.scopus.com/inward/record.url?scp=85066487659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066487659&partnerID=8YFLogxK

M3 - Article

C2 - 28585618

AN - SCOPUS:85066487659

VL - 61

SP - 158

EP - 166

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 2

ER -